Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06566261
PHASE1

ABA-101 in Participants With Progressive Multiple Sclerosis

Sponsor: Abata Therapeutics

View on ClinicalTrials.gov

Summary

This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis. It is the first study of this treatment in humans. After safety is demonstrated with a low dose of ABA-101, a higher dose will be evaluated.

Official title: A Phase 1 Open-label, Single Ascending Dose Study of ABA-101 in Participants With Progressive Multiple Sclerosis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2024-09-11

Completion Date

2027-02

Last Updated

2025-07-03

Healthy Volunteers

No

Interventions

BIOLOGICAL

ABA-101

ABA-101 is a TCR engineered, autologous regulatory T cell (Treg) therapy

Locations (3)

Johns Hopkins University

Baltimore, Maryland, United States

Rutgers, Robert Wood Johnson Medical School

New Brunswick, New Jersey, United States

Cleveland Clinic Mellen Center

Cleveland, Ohio, United States